Tipiracil / Trifluridine: 9 agencies, 2016–2024
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
Assessment has run over 8.8 years, from 10 Mar 2016 at AWMSG (Wales) to 18 Dec 2024 at DMC (Denmark).
DMC (Denmark) changed its position: not recommended on 28 Oct 2021, recommended by 18 Dec 2024, after a resubmission.
No assessment is on file from PHARMAC (New Zealand) and CIPM (Spain), each among the eight highest-volume agencies here.
The file is active: 6 of 22 records date from 2023 or later.
The programme is broad: 10 distinct indication wordings are recorded for tipiracil / trifluridine by the agencies that label one in English (AWMSG, PBAC and SMC).
4 of these 22 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess tipiracil / trifluridine, on 10 Mar 2016; AOTMIT (Poland) did not open a file until 6 Jun 2023 — a wide spread of 7.2 years between the earliest and latest system to look at it.
The record arrives in waves: 5 separate years each carry two or more decisions, spread across 8 years in total.
7 of the 9 agencies here assessed tipiracil / trifluridine more than once, PBAC (Australia) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
9 of the 18 agencies in this archive hold a record for tipiracil / trifluridine.
The full ledger for tipiracil / trifluridine reads 14 recommended, 3 deferred to NICE, 2 not recommended and 2 other, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| DMC (Denmark) | 18 Dec 2024 | Behandling af metastatisk tyk- og endetarmskræft hos voksne patienter, som har modtaget to tidligere behandlinger for me… | Anbefalet | source |
| HAS (France) | 4 Sep 2024 | Indication extension | SMR moderate · ASMR V | source |
| AWMSG (Wales) | 21 Aug 2024 | With bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments | excluded, NICE appraised | source |
| G-BA (Germany) | 15 Feb 2024 | Lonsurf — benefit assessment §35a | added benefit: considerable (hint) | source |
| SMC (Scotland) | 7 Jun 2021 | As monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously trea… | accepted (restricted) | source |
17 further decisions for tipiracil / trifluridine, across 9 agencies, are not shown here. They link to 12 further source documents.
Related molecules
- trifluridine — divergent outcome (recommended vs not recommended) on a shared indication
- polihexanide — same ATC class S01A — Ophthalmologicals
- gimeracil / oteracil / tegafur — also decided by DMC in 2024Q4
- tafamidis — also decided by DMC in 2024Q4
- durvalumab — also decided by DMC in 2024Q4
- axicabtagene ciloleucel — also decided by DMC in 2024Q4
Coverage: 22 decisions for tipiracil / trifluridine from 9 agencies, 2016 to 2024. Data to 7 Sep 2026. ATC class S01A — Ophthalmologicals. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.